Intuniv patient kit draws DDMAC untitled letter

Share this article:
Intuniv patient kit draws DDMAC untitled letter
Intuniv patient kit draws DDMAC untitled letter
Patient materials for Shire's ADHD drug Intuniv presented unsubstantiated effectiveness and superiority claims and downplayed important risk info, said the FDA's Division of Drug Marketing, Advertising and Communication.

In a June 22 untitled letter posted today, DDMAC asked Shire to stop giving out an Intuniv “patient starter kit,” including a parent guide, titration guide and ADHD support guide as well as in-office brochures. The agency said materials, which feature images of a child in a monster suit and “before and after” images, give the impression that the drug will improve individual behavioral problems in children with ADHD. That impression isn't supported by the science, said FDA.

The parent guide also suggested that the drug “improved symptoms day and night,” which the agency said “misleadingly implies that Intuniv is efficacious for a full 24-hour day.”

Some materials failed to present risk information, the agency found. Among other incidences, DDMAC noted that the front side of a branded brochure holder presented effectiveness claims for the drug but fails to present risk information – which is printed on the back of the holder, where the letter noted “it is unlikely to draw the reader's attention.”

“Moreover, the promotional materials further minimize the risks of Intuniv by failing to present risk information with a prominence and readability reasonably comparable with the presentation of claims relating to the effectiveness of the drug,” said the letter. “Specifically, the promotional materials use large and colorful headers to highlight benefits of Intuniv therapy, including a prominent and compelling image of a child in a large monster suit, while the risk information appears in small font and in single-spaced paragraph format, and in many cases only appears at the end of each piece.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...